Position in NBIX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$900,340
+$528,570 QoQ
Shares Held
5,342
+89.3% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#412
of 768 holders
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 76%
Shared 11%
None 13%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Savant Capital, LLC holds $13,041,183 across 15 Drug Manufacturers - Specialty & Generic names. NBIX ranks #6 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HLN |
Haleon plc
|
391,297 | $3,650,801 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
3,845 | $2,083,336 | |
| 3 | VTRS |
Viatris Inc
|
74,919 | $1,189,713 | |
| 4 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
15,478 | $989,818 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
56,536 | $906,272 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
This page
|
5,342 | $900,340 | |
| 7 | LNTH |
Lantheus Holdings, Inc.
|
7,965 | $883,637 | |
| 8 | ZTS |
Zoetis Inc.
|
9,906 | $711,845 |
All Filings in NBIX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $900,340 | 5,342 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $371,770 | 2,822 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $364,644 | 2,571 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $350,528 | 2,497 | Shares | Sole | 2026-03-04 | |
| 2025-06-30 | $302,912 | 2,410 | Shares | Sole | 2026-03-04 | |
| 2024-12-31 | $2,258,119 | 16,543 | Shares | Sole | 2025-01-29 | |
| 2024-06-30 | $986,130 | 7,163 | Shares | Sole | 2024-08-05 | |
| 2024-03-31 | $2,150,586 | 15,593 | Shares | Sole | 2024-05-06 | |
| No filing history on record for this holder in this stock. | ||||||